Cytogenetic risk score maintains its prognostic significance in aml patients with detectable measurable residual disease undergoing transplantation in remission: on behalf of the alwp/ebmt - Université de Lille Accéder directement au contenu
Article Dans Une Revue American Journal of Hematology Année : 2020

Cytogenetic risk score maintains its prognostic significance in aml patients with detectable measurable residual disease undergoing transplantation in remission: on behalf of the alwp/ebmt

Résumé

While evidence for measurable residual disease (MRD) is a harbinger of inferior outcome in acute myeloid leukemia (AML) patients referred for allogeneic stem cell transplantation (allo-SCT), the exact clinical trajectory of specific patient subsets in this clinical setting is undefined. Using a recently published prognostic cytogenetic model (Canaani et al. Leukemia 2019) we evaluated whether this model applied also to studies of patients with positive MRD. The analysis comprised MRD+wtwt+

Dates et versions

hal-04428990 , version 1 (31-01-2024)

Identifiants

Citer

Arnon Nagler, Myriam Labopin, Jonathan Canaani, Riitta Niittyvuopio, Gerard Socie, et al.. Cytogenetic risk score maintains its prognostic significance in aml patients with detectable measurable residual disease undergoing transplantation in remission: on behalf of the alwp/ebmt. American Journal of Hematology, 2020, American Journal of Hematology, ⟨10.1002/ajh.25905⟩. ⟨hal-04428990⟩
5 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More